Allarity Therapeutics Aktie

Allarity Therapeutics has received a CLIA registration certificate for its laboratory in Hørsholm, Denmark, enabling DRP® biomarker tests to be conducted internally for US-approved clinical trials. The certification is expected to shorten turnaround times, reduce long-term costs by cutting outsourcing, and support development of lead candidate Stenoparib for advanced, platinum-resistant ovarian cancer. The lab will also be able to offer DRP and laboratory services to third parties. At the same time, the company faces high cash burn; market capitalization is around $19 million and free cash flow was recently negative. » More on de.investing.com